Article metrics

Download PDFPDF

Extended report
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate
Free

 

Online download statistics by month:

Online download statistics by month: April 2013 to April 2021

AbstractFullPdf
Apr 20134492978
May 20131822745
Jun 20131382119
Jul 20131301313
Aug 20132173155274
Sep 201372360110
Oct 20134055468
Nov 20132654458
Dec 20131485632
Jan 2014864642
Feb 20141546864
Mar 2014866052
Apr 2014723242
May 2014764335
Jun 2014782839
Jul 2014802940
Aug 2014802647
Sep 2014471430
Oct 2014754539
Nov 2014552220
Dec 20143579
Jan 2015242421
Feb 2015191315
Mar 2015351715
Apr 2015311413
May 2015251715
Jun 201535119
Jul 2015261912
Aug 201527137
Sep 2015561910
Oct 20151454
Nov 20152144
Dec 201550169
Jan 2016421110
Feb 201642107
Mar 2016221419
Apr 201623718
May 2016341814
Jun 20161873
Jul 201633915
Aug 201627914
Sep 2016361515
Oct 201633339
Nov 2016404710
Dec 2016311412
Jan 201720116
Feb 201713149
Mar 20176113
Apr 20172198
May 201717297
Jun 201714196
Jul 201721158
Aug 201735213
Sep 201739276
Oct 201738289
Nov 201750328
Dec 201718173
Jan 2018423310
Feb 201835309
Mar 2018191712
Apr 2018342411
May 2018684016
Jun 2018433310
Jul 201835264
Aug 2018604211
Sep 201850344
Oct 201849374
Nov 201872526
Dec 201865472
Jan 201975475
Feb 201953363
Mar 201930109
Apr 201916136
May 201914117
Jun 2019559
Jul 2019241610
Aug 201919137
Sep 201910103
Oct 201923217
Nov 20191074
Dec 2019211410
Jan 2020332014
Feb 202031197
Mar 2020141411
Apr 202021136
May 2020131316
Jun 20201393
Jul 20201391
Aug 20201685
Sep 202018151
Oct 2020251812
Nov 202023179
Dec 202015114
Jan 202117179
Feb 202116128
Mar 2021181411
Apr 202129197
Total774123341815